Gilead HCV Sales Plateau, But Maintain Dominant Market Share
This article was originally published in Scrip
Gilead Sciences Inc. continues to bring in blockbuster revenues on sofosbuvir-based hepatitis C regimens and to maintain a dominant market share in that space, but HCV product sales leveled off from the second quarter due to several factors, the company reported during its third quarter earnings call on Oct. 27.
You may also be interested in...
Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.
Lilly plans a head-to-head study of donanemab versus Biogen’s Aduhelm to see which clears amyloid plaque better and has begun a rolling BLA toward accelerated approval of the Alzheimer’s drug.
Metacrine halts development of its FXR agonist compounds in NASH and turn its focus to inflammatory bowel disease. Firm plans Phase II ulcerative colitis study in 2022 with MET642.